NEW YORK – Worcester, Massachusetts-based Mustang Bio on Thursday announced that the first patient has been dosed in a Phase I/II clinical trial evaluating Mustang's investigational CD123-targeted CAR T cell therapy MB-102, a treatment for patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia, and high-risk myelodysplastic syndrome (hrMDS).